Journal of Pharmacy and Pharmacology · 1973 · 12 citations · 10 references
PharmacyPharmacokineticsPharmacologyBioavailabilityDrug MetabolismExcretionBiliary ExcretionDrug DispositionEnterohepatic CirculationGastrointestinal AbsorptionGastrointestinal PharmacologyIntestinal AbsorptionBiliary Drug ExcretionBiliary Drug MetabolismBiliary Excretion KineticsBiliary Excretion PathwaysGastrointestinal Drug MetabolismHepatobiliary Drug DispositionSmall Intestine Anatomy
Abstract Butylscopolamine was labelled with 14C and its gastrointestinal absorption, biliary and urinary excretion, enterohepatic circulation and gastrointestinal distribution were examined in anaesthetized rats. Biliary excretion was the main elimination route of intra-portally administered [14C]butylscopolamine, with 42% of the dose recovered in the bile during 12 h. About 6% of the radioactivity administered orally as [14C]butylscopolamine was excreted in the bile and 1.2 % in the urine during 24 h, which indicates poor gastrointestinal absorption of butylscopolamine in the rat. When collected radioactive bile was readministered intrajejunally, only about 7% of the radioactivity was recovered in bile and urine during 12 h, which suggests that only a small fraction of butylscopolamine and its metabolites engage in an enterohepatic circulation. After oral administration of [14C]butylscopolamine, radioactivity was found to accumulate in the wall of the distal small intestine, and about 20% of the dose was found in this tissue 24 h after drug administration. As a result, local anti-acetylcholine effects of butylscopolamine might be expected.
10
HUMAN PHARMACOLOGY OF HYOSCINE BUTYLBROMIDE
Andrew Herxheimer, L Haefeli · The Lancet · 1966 · 66 citations